Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s stock price gapped down before the market opened on Monday . The stock had previously closed at $17.15, but opened at $16.25. Telix Pharmaceuticals shares last traded at $16.22, with a volume of 18,490 shares trading hands.
Analyst Upgrades and Downgrades
Several brokerages recently commented on TLX. Wedbush reiterated an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, June 12th. William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, March 12th.
View Our Latest Research Report on Telix Pharmaceuticals
Telix Pharmaceuticals Trading Up 2.6%
The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99. The firm has a fifty day simple moving average of $17.04 and a 200-day simple moving average of $16.94.
Institutional Investors Weigh In On Telix Pharmaceuticals
A hedge fund recently bought a new stake in Telix Pharmaceuticals stock. ABC Arbitrage SA acquired a new position in shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 26,939 shares of the company's stock, valued at approximately $451,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Stories
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
